Benefit of treatment based on indapamide mostly combined with perindopril on mortality and cardiovascular outcomes: a pooled analysis of four trials
Authors:
Open Access
- 19 January 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 41 (3) , 508-515
Abstract
Objective: The aim of this study was to assess the reduction in all-cause death and cardiovascular outcomes associated with the administration of the thiazide-like diuretic indapamide monotherapy or in combination with perindopril as a blood pressure lowering drug in randomized controlled trials (RCTs). Method: Aggregate data from four published RCTs conducted versus matching placebo were pooled: PATS, a 2-year study (indapamide), and PROGRESS, a 4-year study (indapamide and perindopril), both in patients with a history of stroke or transient ischemic attack; ADVANCE, a 4-year study in patients with type 2 diabetes and cardiovascular risk factor (single-pill combination perindopril/indapamide) and HYVET, a 2-year study in very elderly hypertensive individuals (indapamide and an option of perindopril). The pooled effect (fixed and random) estimate (hazard ratio) was reported with corresponding 95% confidence intervals and P values. Treatment discontinuations were also analysed to assess the net benefit of the treatment. Results: The population involved 24 194 patients (active: 12 113, placebo: 12 081). The fixed-effects meta-analysis of the three mortality endpoints found low statistical heterogeneity (I 2 = 0). Statistically significant risk reductions in the indapamide with or without perindopril-treated patients as compared to placebo were observed for all-cause death (−15%), cardiovascular death (−21%), fatal stroke (−36%) and all strokes (−27%). Other cardiovascular outcomes were improved (risk reduction, 22 to 36%). As expected, discontinuation rates for safety (two studies) were higher in the active group (6.4 vs. 3.9%), while they were similar when discontinuation for any reason is concerned (18.4 vs. 18.0%). Conclusion: Across medium to high cardiovascular risk population, long-term indapamide, mostly combined with perindopril-based treatment, provided evidence of benefit on mortality and morbidity.Keywords
This publication has 58 references indexed in Scilit:
- Evidence-Based Diuretic Therapy for Improving Cardiovascular Prognosis in Systemic HypertensionThe American Journal of Cardiology, 2011
- Antihypertensive Efficacy of Hydrochlorothiazide as Evaluated by Ambulatory Blood Pressure MonitoringJACC, 2011
- Treatment of hypertension in patients 80 years and older: the lower the better? A meta-analysis of randomized controlled trialsJournal Of Hypertension, 2010
- Blood pressure lowering efficacy of diuretics as second-line therapy for primary hypertensionCochrane Database of Systematic Reviews, 2009
- Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literatureHypertension Research, 2009
- Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studiesBMJ, 2009
- Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trialThe Lancet, 2007
- Indapamide Sustained ReleaseDrugs, 2006
- Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension, 2003
- Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular diseaseEuropean Heart Journal, 2003